APA (7th ed.) Citation

Darb-Esfahani, S., Stenzinger, A., Endris, V., & Sinn, P. (2016). Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. OncoTarget, 7(42), . https://doi.org/10.18632/oncotarget.11891

Chicago Style (17th ed.) Citation

Darb-Esfahani, Silvia, Albrecht Stenzinger, Volker Endris, and Peter Sinn. "Role of TP53 Mutations in Triple Negative and HER2-positive Breast Cancer Treated with Neoadjuvant Anthracycline/taxane-based Chemotherapy." OncoTarget 7, no. 42 (2016). https://doi.org/10.18632/oncotarget.11891.

MLA (9th ed.) Citation

Darb-Esfahani, Silvia, et al. "Role of TP53 Mutations in Triple Negative and HER2-positive Breast Cancer Treated with Neoadjuvant Anthracycline/taxane-based Chemotherapy." OncoTarget, vol. 7, no. 42, 2016, https://doi.org/10.18632/oncotarget.11891.